INHIBITORS OF BETA AMYLOID PRODUCTION

Novel sulfonamide compounds useful in the treatment of conditions related to the production of beta-amyloid are described, as are routes to their preparation. The sulfonamide compounds are of the following structure, wherein R4-R3 are defined herein. Also provided are pharmaceutical compositions con...

Full description

Saved in:
Bibliographic Details
Main Authors HARRISON, BOYD, L, MORRIS, KOI, M, SPRINGER, DANE, M, KUBRAK, DENNIS, M, KREFT, ANTHONY, F., III, CAGGIANO, THOMAS, J
Format Patent
LanguageEnglish
French
Published 22.01.2009
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Novel sulfonamide compounds useful in the treatment of conditions related to the production of beta-amyloid are described, as are routes to their preparation. The sulfonamide compounds are of the following structure, wherein R4-R3 are defined herein. Also provided are pharmaceutical compositions containing these compounds and/or prodrugs of these compounds and a physiologically compatible carrier. These compounds are specifically useful for inhibiting beta amyloid production, and treating Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome. L'invention concerne de nouveaux composés sulfonamide utiles dans le traitement d'affections liées à la production de bêta amyloïde, ainsi que des voies pour leur préparation. Les composés sulfonamide ont la structure suivante, dans laquelle R4 et R3 sont définis ici. Sont également proposés des compositions pharmaceutiques contenant ces composés et/ou des promédicaments de ces composés et un support physiologiquement compatible. Ces composés sont spécialement utiles pour inhiber la production de bêta amyloïde et traiter la maladie d'Alzheimer, une angiopathie d'amyloïde, une angiopathie amyloïde cérébrale, une amyloïdose systémique, une hémorragie cérébrale héréditaire avec amyloïdose du type Dutch, y compris myosite corporelle, trouble cognitif léger (MCI) et syndrome de Down.
Bibliography:Application Number: WO2008US69942